Pulmonary Arterial Hypertension

• Published in: Journal of the American College of Cardiology Vol. 51; no. 16; pp. 1527 - 1538
• Main Authors: Chin, Kelly M., Rubin, Lewis J.
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 22.04.2008; Elsevier Science; Elsevier Limited
• Subjects: Algorithms; Antihypertensive Agents - therapeutic use; Biological and medical sciences; Cardiology; Cardiology. Vascular system; Cardiovascular; Disease Progression; Drug therapy; Humans; Hypertension, Pulmonary - classification; Hypertension, Pulmonary - complications; Hypertension, Pulmonary - drug therapy; Internal Medicine; Medical sciences; Muscular system; Mutation; Nitric oxide; Pneumology; Prognosis; Pulmonary Artery - pathology; Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases; Risk Factors; Rodents; CHF; NO; BMPR; HIV; RV; PAH; bone morphogenetic protein receptor; right ventricle/ventricular; nitric oxide; human immunodeficiency virus; congestive heart failure; pulmonary arterial hypertension; Cardiovascular disease; Circulatory system; Cardiology; Respiratory disease; Artery; Pulmonary hypertension

Pulmonary Arterial Hypertension Kelly M. Chin, Lewis J. Rubin Significant advances in the treatment of pulmonary arterial hypertension have occurred over the last 10 years, starting with the approval of epoprostenol in 1998, followed by the development of subcutaneous and inhaled prostacyclins, oral...